The fate of (−)1-(benzofuran-2-yl)-2-propylaminopentane · HCl, (−)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain

@article{Magyar2010TheFO,
  title={The fate of (−)1-(benzofuran-2-yl)-2-propylaminopentane · HCl, (−)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain},
  author={K{\'a}lm{\'a}n Magyar and J{\'o}zsef Lengyel and Andrea Bolehovszky and Bertha Knoll and Iidik{\'o} Miklya and Joseph Knoll},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  year={2010},
  volume={27},
  pages={157-161}
}
  • K. Magyar, J. Lengyel, J. Knoll
  • Published 1 July 2002
  • Medicine, Biology
  • European Journal of Drug Metabolism and Pharmacokinetics
SummaryOur aim was to study the fate of (−)-1-(benzofuran-2-yl)-2-propylaminopentane · HCl [(−)-BPAP] in rats, using radio-labelled compound [(−)-BPAP-14C]. Radioactivity was measured by liquid scintillation technique and the tissue concentrations of radioactivity were calculated on the basis of the specific activity of (−)-BPAP-14C and the values are given in ngeq./g.Radioactivity was well absorbed after i.p., s.c. and oral treatment and Cmax has been reached at 30 to 60 min following drug… 
1 Citations

References

SHOWING 1-10 OF 10 REFERENCES
(−)1‐(Benzofuran‐2‐yl)‐2‐propylaminopentane, [(−)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
TLDR
By changing the aromatic ring in PPAP the authors developed highly potent and selective CAE/SAE substances, structurally unrelated to the amphetamines, which significantly enhanced the activity of the catecholaminergic and serotoninergic neurons in the brain 30 min after acute injection of (−)BPAP.
Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.
TLDR
This review summarizes the physiologic and pharmacologic arguments in favor of a peculiar lifelong prophylactic medication with reasonable chances to keep in check brain aging and decrease the precipitation of age-related neurological diseases.
(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
  • J. Knoll
  • Biology, Psychology
    Pharmacology & toxicology
  • 1998
TLDR
It may be supposed that a prophylactic low dose administration of a safe catecholaminergic activity enhancer substance during the postdevelopmental phase of life will slow the age-related decline of behavioral performances, delay natural death and decrease susceptibility to Parkinson's disease and Alzheimer's disease.
-)Deprenyl and (-) l-phenyl-z-propylaminopentane, [(-)pPAP]. act primarily as potent stimulants of action potential- transmitter release coupling in the catecholaminergic neurones
  • Life Sci.,
  • 1996
Deprenyl : the anti - aging psychoenergizer
  • Anti - Aging Bulletin
  • 2001
Outlines of a drug strategy to slow brain aging
  • Neuropsychopharmacologia Hungarica,
  • 2000